Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Berchuck

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
Genes, Chromosomes & Cancer|November 20, 1997
Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomasC Choi, S Cho, I Horikawa, et al.
Molecular Carcinogenesis|August 1, 1997
Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridizationJ P Packenham, S du Manoir, E Schrock, et al.
Cancer Research|June 1, 1991
Overexpression and mutation of p53 in epithelial ovarian cancerJ R Marks, A M Davidoff, B J Kerns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Frequency of germline and somatic BRCA1 mutations in ovarian cancerA Berchuck, K A Heron, M E Carney, et al.
Cancer|December 26, 2001
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisalC van Haaften-Day, Y Shen, F Xu, et al.
Cancer Research|March 25, 1992
Overexpression and mutation of p53 in endometrial carcinomaM F Kohler, A Berchuck, A M Davidoff, et al.
The New England Journal of Medicine|November 7, 1996
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1S C Rubin, I Benjamin, K Behbakht, et al.
Oncogene|October 7, 2008
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cellsT Baba, P A Convery, N Matsumura, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2007
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancerJ D Wright, A A Secord, T M Numnum, et al.
Gynecologic Oncology|January 16, 2020
Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancerK Bixel, M Vetter, B Davidson, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
Genes, Chromosomes & Cancer|November 20, 1997
Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomasC Choi, S Cho, I Horikawa, et al.
Molecular Carcinogenesis|August 1, 1997
Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridizationJ P Packenham, S du Manoir, E Schrock, et al.
Cancer Research|June 1, 1991
Overexpression and mutation of p53 in epithelial ovarian cancerJ R Marks, A M Davidoff, B J Kerns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Frequency of germline and somatic BRCA1 mutations in ovarian cancerA Berchuck, K A Heron, M E Carney, et al.
Cancer|December 26, 2001
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisalC van Haaften-Day, Y Shen, F Xu, et al.
Cancer Research|March 25, 1992
Overexpression and mutation of p53 in endometrial carcinomaM F Kohler, A Berchuck, A M Davidoff, et al.
The New England Journal of Medicine|November 7, 1996
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1S C Rubin, I Benjamin, K Behbakht, et al.
Oncogene|October 7, 2008
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cellsT Baba, P A Convery, N Matsumura, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2007
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancerJ D Wright, A A Secord, T M Numnum, et al.
Gynecologic Oncology|January 16, 2020
Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancerK Bixel, M Vetter, B Davidson, et al.
Pageof 20